doi:

DOI: 10.3724/SP.J.1264.2011.00022

Chinese Journal of Multiple Organ Diseases in the Elderly (中华老年多器官疾病杂志) 2011/10:4 PP.377-380

Recent advances in the diagnosis and treatment of non-pulmonary arterial hypertension pulmonary hypertension


Abstract:
Pulmonary hypertension(PH) is a heterogeneous group of disorders characterized by increased pulmonary vascular resistance(PVR). The term PH pertains to the hemodynamic profile. PH can be found in different clinical conditions. The non-pulmonary arterial hypertension pulmonary hypertension(non-PAH PH) refers to those forms of PH that are found in group 2 to 5 of the current classification of PH. They included pulmonary hypertension due to left heart disease, pulmonary hypertension due to lung diseases and hypoxemia, chronic thromboembolic pulmonary hypertension, and other diseases. Some advances has been made for the diagnosis and medical therapy of pulmonary arterial hypertension(PAH), but PAH is usually severe and overall quite rare. Non-PAH PH is much more common than PAH, and has been less well studied, especially in terms of diagnosis and medical therapy. The di-agnosis and medical therapy of non-PAH PH would be the hot topics and it is important to conduct further studies.

Key words:pulmonary hypertension, diagnosis, therapy

ReleaseDate:2014-07-21 15:56:27



[1] Hoeper MM, Barberà JA, Channick RN, et al. Diagnosis, assessment, and treatment of non-pulmonary arterial hypertension pulmonary hypertension[J]. J Am Coll Cardiol, 2009, 54(1 Suppl): S85-96.

[2] Escribano Subias P, Barberà Mir JA, Suberviola V. Current diagnostic and prognostic assessment of pulmonary hypertension[J]. Rev Esp Cardiol, 2010, 63(5): 583-596.

[3] Zakynthinos E, Daniil Z, Papanikolaou J, et al. Pulmonary hypertension in COPD: pathophysiology and therapeutic targets[J]. Curr Drug Targets, 2011, 12(4): 501-513.

[4] Leuchte HH, El Nounou M, Tuerpe JC, et al. N-terminal pro-brain natriuretic peptide and renal insufficiency as predictors of mortality in pulmonary hypertension[J]. Chest, 2007, 131(2): 402-409.

[5] Rietema H, Holverda S, Bogaard HJ, et al. Silde-nafil treatment in COPD does not affect stroke volume or exercise capacity[J]. Eur Respir J, 2008, 31(4): 759-764.

[5] Rietema H, Holverda S, Bogaard HJ, et al. Sildenafil treatment in COPD does not affect stroke volume or exercise capacity[J]. Eur Respir J, 2008, 31(4): 759-764.

[6] Stolz D, Rasch H, Linka A, et al. A randomised, controlled trial of bosentan in severe COPD[J]. Eur Respir J, 2008, 32(3): 619-628.

[7] Condliffe R, Kiely DG, Gibbs JS, et al. Prognostic and etiological factors in chronic thromboembolic pulmonary hypertension[J]. Eur Respir J, 2009, 33(2): 332-338.

[8] Bonderman D, Skoro-Sajer N, Jakowitsch J, et al. Predictors of outcome in chronic thromboembolic pulmonary hypertension[J]. Circulation, 2007, 115(16): 2153-2158.

[9] Keogh AM, Mayer E, Benza RL, et al. Interventional and surgical modalities of treatment in pulmonary hypertension[J]. Am Coll Cardiol, 2009, 54(1 Suppl): S67-77.

[10] Hoeper MM, Mayer E, Simonneau G, et al. Chronic thromboembolic pulmonary hypertension[J]. Circulation, 2006, 113(16): 2011-2020.

[11] Oudiz RJ. Pulmonary hypertension associated with left-sided heart disease[J].Clin Chest Med, 2007, 28(1): 233-241.

[12] Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart disease and stroke statistics—2010 update: a report from the American Heart Association[J]. Circulation, 2010, 121(7): e46-e215.

[13] Grignola JC. Hemodynamic assessment of pulmonary hypertension[J]. World J Cardiol, 2011, 3(1): 10-17.

[14] Delgado JF. The pulmonary circulation in heart failure[J]. Rev Esp Cardiol, 2010, 63(3): 334-345.

[15] Kirkby NS, Hadoke PW, Bagnall AJ, et al. The endothelin system as a therapeutic target in cardiovascular disease: great expectations or bleak house[J]? Br J Pharmacol, 2008, 153(6): 1105-1119.

PDF